Sobi and Apellis: Aspaveli®/ Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases
07.08.2025 - 18:03:32 | prnewswire.co.uk
View original content:https://www.prnewswire.co.uk/news-releases/sobi-and-apellis-aspaveliempaveli-demonstrates-sustained-one-year-efficacy-in-phase-3-study-for-rare-kidney-diseases-302475366.html
en | boerse | 67995545 |
